Koppers Holdings (NYSE:KOP) reported first-quarter revenue that reached $455.3 million as the company moves to streamline its manufacturing footprint and navigate volatile energy costs.
Artiva Biotherapeutics (NASDAQ:ARTV) has reached a pivotal regulatory milestone, securing FDA alignment for a single Phase 3 registrational trial of its lead candidate, AlloNK, following positive initial data in refractory rheumatoid arthritis (RA).
TeraWulf (NASDAQ:WULF) reported first-quarter 2026 financial results on Friday, highlighting a significant strategic shift toward high-performance computing (HPC) and the acquisition of substantial new power capacity.
Starwood Property Trust (NYSE:STWD) demonstrated a significant uptick in investment activity during the first quarter of 2026, leveraging its scale to deploy billions into high-yielding credit and infrastructure assets.
Creative Media & Community Trust (NASDAQ:CMCT) reported operating results for the first quarter of 2026, characterized by a dual focus on operational improvement in residential assets and a sweeping overhaul of its capital structure.
Enbridge (NYSE:ENB) maintained its steady financial trajectory in the first quarter of 2026, delivering results that aligned with its long-term growth outlook.
Calumet (NASDAQ:CLMT) reported a first-quarter 2026 net loss of $317 million, or $3.64 per share, as the company navigated a period of heavy maintenance and non-cash accounting volatility.
Burford Capital (NYSE:BUR) released its unaudited first-quarter 2026 financial results on May 8, 2026, characterized by a stark contrast between non-cash accounting charges and a record level of balance sheet liquidity.
Construction Partners (NASDAQ:ROAD) reported explosive growth for its fiscal second quarter of 2026, benefiting from a robust infrastructure environment in the Southeastern United States and improved operational execution.
Wendy’s (NASDAQ:WEN) is doubling down on its international growth strategy to offset a challenging domestic environment, announcing a landmark franchise agreement in China alongside its first-quarter 2026 financial results.
ANI Pharmaceuticals (NASDAQ:ANIP) delivered a robust first-quarter performance for 2026, fueled by the continued rapid expansion of its Rare Disease segment.
RE/MAX Holdings (NYSE:RMAX) reported its first-quarter 2026 financial results against the backdrop of a transformative merger agreement with The Real Brokerage (NASDAQ:REAX).
-1-640x359.webp&w=3840&q=75)
